Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Co-morbid Allergic Rhinitis and Allergic Asthma
NCT06189742Phase 2Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tezepelumab in asthma, allergic rhinitis (AR). Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06189742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189742.